POM-V
Prescription Required
Companion Animal
Propofol-Lipuro Vet 10 mg/ml Emulsion for Injection
Active ingredient: Propofol
Form
Injection
Species
Cats
Dogs
Manufacturer
B. Braun Melsungen AG
VMD MA No.
03551/4001
What it's used for
For induction and short-term maintenance of general anaesthesia using incremental doses to effect. For induction of general anaesthesia where maintenance i...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Propofol
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Propofol-Lipuro Vet 10 mg/ml Emulsion for Injection — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
For induction and short-term maintenance of general anaesthesia using
incremental doses to effect.
For induction of general anaesthesia where maintenance is provided by inhalation
anaesthetics.
incremental doses to effect.
For induction of general anaesthesia where maintenance is provided by inhalation
anaesthetics.
Before opening the container, the product should be inspected visually for the
absence of visible droplets or extraneous foreign particles and discarded if
present. The container should be shaken gently but thoroughly before opening.
Induction: The induction dose is computed according to bodyweight and may be
administered to effect over a period of 10 – 40 seconds. Alternatively, the
computed dose may be given in full as a single bolus. The induction dose is
reduced by the use of premedicants.
It should be noted that the dose rates shown are for guidance and in practice the
dose rate should be based on response.
The average induction dose for dogs and cats, either unpremedicated or when
premedicated with a non alpha-2-agonist tranquilliser such as acepromazine, is as
follows:
Dose rate
mg/ kg
bodyweight
Dose volume
ml/ kg bodyweight
DogsUnpremedicated6.56.5 ml/ 10kgPremedicated4.04.0 ml/ 10 kgCatsUnpremedicated8.02.0 ml/ 2.5 kgPremedicated6.01.5 ml/ 2.5 kg
Maintenance by Propofol-Lipuro Vet 10 mg/ml: Where anaesthesia is maintained
by incremental injections, the dose rate will vary between animals. Incremental
doses should be given to effect. Experience in clinical trials has shown that doses
of around 1ml per 4.0 – 8.0 kg bodyweight sustain anaesthesia for periods of up to
five minutes.
Maintenance by inhalation agents: Where inhalation agents are used to maintain
general anaesthesia, clinical experience indicates that there may be a need to use
a higher initial concentration of inhalation agent than is normally the case following
induction with barbiturate agents such as thiopentone.
The emulsion should not be mixed with other therapeutic agents or infusion fluids
prior to administration.
Propofol-Lipuro Vet 10 mg/ml does not contain an antimicrobial preservative. It
should be used immediately after opening. Any product remaining in the container
following withdrawal of the required dose should be discarded.
Continuous and prolonged exposure may lead to slower recovery, particularly in
cats.
absence of visible droplets or extraneous foreign particles and discarded if
present. The container should be shaken gently but thoroughly before opening.
Induction: The induction dose is computed according to bodyweight and may be
administered to effect over a period of 10 – 40 seconds. Alternatively, the
computed dose may be given in full as a single bolus. The induction dose is
reduced by the use of premedicants.
It should be noted that the dose rates shown are for guidance and in practice the
dose rate should be based on response.
The average induction dose for dogs and cats, either unpremedicated or when
premedicated with a non alpha-2-agonist tranquilliser such as acepromazine, is as
follows:
Dose rate
mg/ kg
bodyweight
Dose volume
ml/ kg bodyweight
DogsUnpremedicated6.56.5 ml/ 10kgPremedicated4.04.0 ml/ 10 kgCatsUnpremedicated8.02.0 ml/ 2.5 kgPremedicated6.01.5 ml/ 2.5 kg
Maintenance by Propofol-Lipuro Vet 10 mg/ml: Where anaesthesia is maintained
by incremental injections, the dose rate will vary between animals. Incremental
doses should be given to effect. Experience in clinical trials has shown that doses
of around 1ml per 4.0 – 8.0 kg bodyweight sustain anaesthesia for periods of up to
five minutes.
Maintenance by inhalation agents: Where inhalation agents are used to maintain
general anaesthesia, clinical experience indicates that there may be a need to use
a higher initial concentration of inhalation agent than is normally the case following
induction with barbiturate agents such as thiopentone.
The emulsion should not be mixed with other therapeutic agents or infusion fluids
prior to administration.
Propofol-Lipuro Vet 10 mg/ml does not contain an antimicrobial preservative. It
should be used immediately after opening. Any product remaining in the container
following withdrawal of the required dose should be discarded.
Continuous and prolonged exposure may lead to slower recovery, particularly in
cats.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
excipients.
Dogs
Very common (>1 animal / 10 animals
treated)
ApnoeaCommon (1 to 10 animals / 100 animals
treated):
Excitation Arrhythmia, Bradycardia,
Hypotension, Hypertension
a
Emesis, Hypersalivation, Retching
Paddling, Myoclonus, Nystagmus,
Opisthotonus, Recovery prolonged
b
Sneezing
Face/nose rubbing
Uncommon (1 to 10 animals / 1 000
animals treated):
Injection site pain
c
Hyperglycemia
a
If propofol is used without premedication as a sole agent in induction of
anaesthesia, a short transient increase of arterial blood pressure can be observed.
b
Slow recovery
c
After intravenous administration
Cats
Very common (>1 animal / 10 animals
treated)
ApnoeaCommon (1 to 10 animals / 100 animals
treated):
Excitation
Arrhythmia, Bradycardia, Hypotension
Emesis, Hypersalivation, Retching
Paddling, Myoclonus, Nystagmus,
Opisthotonos, Recovery prolonged
Sneezing
Face/nose rubbing
Uncommon (1 to 10 animals / 1 000 Injection site pain
a
animals treated):Diarrhoea
b
Facial oedema
b,c
Hyperglycemia, Heinz body anaemia
b
Anorexia
b
a
After intravenous administration.
b
In cats undergoing repeated anaesthesia. Limiting repeated anaesthesia to
intervals of more than 48 hours will reduce the likelihood. The effects are generally
transient and resolve on their own.
c
Mild facial oedema.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the
national competent authority via the national reporting system. See the package
leaflet for respective contact details.
Very common (>1 animal / 10 animals
treated)
ApnoeaCommon (1 to 10 animals / 100 animals
treated):
Excitation Arrhythmia, Bradycardia,
Hypotension, Hypertension
a
Emesis, Hypersalivation, Retching
Paddling, Myoclonus, Nystagmus,
Opisthotonus, Recovery prolonged
b
Sneezing
Face/nose rubbing
Uncommon (1 to 10 animals / 1 000
animals treated):
Injection site pain
c
Hyperglycemia
a
If propofol is used without premedication as a sole agent in induction of
anaesthesia, a short transient increase of arterial blood pressure can be observed.
b
Slow recovery
c
After intravenous administration
Cats
Very common (>1 animal / 10 animals
treated)
ApnoeaCommon (1 to 10 animals / 100 animals
treated):
Excitation
Arrhythmia, Bradycardia, Hypotension
Emesis, Hypersalivation, Retching
Paddling, Myoclonus, Nystagmus,
Opisthotonos, Recovery prolonged
Sneezing
Face/nose rubbing
Uncommon (1 to 10 animals / 1 000 Injection site pain
a
animals treated):Diarrhoea
b
Facial oedema
b,c
Hyperglycemia, Heinz body anaemia
b
Anorexia
b
a
After intravenous administration.
b
In cats undergoing repeated anaesthesia. Limiting repeated anaesthesia to
intervals of more than 48 hours will reduce the likelihood. The effects are generally
transient and resolve on their own.
c
Mild facial oedema.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the
national competent authority via the national reporting system. See the package
leaflet for respective contact details.
The product is a stable emulsion; discard the container if phase separation is
observed.
If injected slowly, an inadequate plane of anaesthesia can occur.
Special precautions for safe use in the target species:
During induction of anaesthesia, mild hypotension and transient apnoea, similar to
effects with other intravenous anaesthetic agents, may occur. Facilities for the
maintenance of a patent airway, artificial ventilation and oxygen enrichment should
be available.
Following induction of anaesthesia, the use of an endotracheal tube is
recommended. Increased levels of carbon dioxide in blood have been reported
with increased duration of propofol anaesthesia. It is advisable to administer
supplemental oxygen during maintenance of anaesthesia. In addition the need for
assisted ventilation should be considered during prolonged anaesthesia.
If the veterinary medicinal product is injected too rapidly, cardiopulmonary
depression may occur (apnoea, bradycardia, hypotension).
As with other intravenous anaesthetic agents, caution should be exercised in dogs
and cats with cardiac, respiratory, renal or hepatic impairment, or in hypovolaemic
or debilitated animals.
Propofol may increase blood glucose metabolism and insulin secretion in healthy
dogs. In the absence of safety data in diabetic animals, use only after a benefit/risk
assessment by the veterinarian.
Care should be taken when administering the veterinary medicinal product to
patients with hypoproteinaemia, hyperlipidaemia or very thin animals since these
animals may be more susceptible to adverse effects.
The safety of the veterinary medicinal product has not been established in dogs or
cats younger than 4 months and should be used in these animals only according
to the risk/benefit assessment by the responsible veterinarian.
It has been reported that the clearance of propofol is slower in overweight/obese
animals and dogs over 8 years of age. Extra care should be taken when
administering the veterinary medicinal product to these animals; in particular, a
lower dose of propofol may be adequate for induction and maintenance in such
cases. Sighthounds have been reported to show a slower clearance of propofol
and may have a slightly longer duration of recovery from anaesthesia compared to
other breeds of dog.
Propofol does not have analgesic properties, therefore supplementary analgesic
agents should be provided in cases where procedures are anticipated to be
painful. When propofol is used concomitantly with opioids, an anticholinergic agent
(e.g. atropine) may be used in cases of bradycardia according to the benefit/risk
assessment by the responsible veterinarian. See section 3.8.
Use aseptic techniques when administering the product as it does not contain an
antimicrobial preservative.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This is a potent drug: particular care should be taken to avoid accidental self-
administration. Preferably use a guarded needle until the moment of injection.
Ampoules, particularly, should be opened with care to avoid cutting oneself.
Wash off splashes from the skin and eyes immediately.
In the case of accidental self-administration, seek medical advice immediately and
show the package leaflet or label to the physician, but DO NOT DRIVE as
sedation may occur.
Advice to doctor: Do not leave patient unattended. Maintain airways and give
symptomatic and supportive treatment.
Special precautions for the protection of the environment
Not applicable.
observed.
If injected slowly, an inadequate plane of anaesthesia can occur.
Special precautions for safe use in the target species:
During induction of anaesthesia, mild hypotension and transient apnoea, similar to
effects with other intravenous anaesthetic agents, may occur. Facilities for the
maintenance of a patent airway, artificial ventilation and oxygen enrichment should
be available.
Following induction of anaesthesia, the use of an endotracheal tube is
recommended. Increased levels of carbon dioxide in blood have been reported
with increased duration of propofol anaesthesia. It is advisable to administer
supplemental oxygen during maintenance of anaesthesia. In addition the need for
assisted ventilation should be considered during prolonged anaesthesia.
If the veterinary medicinal product is injected too rapidly, cardiopulmonary
depression may occur (apnoea, bradycardia, hypotension).
As with other intravenous anaesthetic agents, caution should be exercised in dogs
and cats with cardiac, respiratory, renal or hepatic impairment, or in hypovolaemic
or debilitated animals.
Propofol may increase blood glucose metabolism and insulin secretion in healthy
dogs. In the absence of safety data in diabetic animals, use only after a benefit/risk
assessment by the veterinarian.
Care should be taken when administering the veterinary medicinal product to
patients with hypoproteinaemia, hyperlipidaemia or very thin animals since these
animals may be more susceptible to adverse effects.
The safety of the veterinary medicinal product has not been established in dogs or
cats younger than 4 months and should be used in these animals only according
to the risk/benefit assessment by the responsible veterinarian.
It has been reported that the clearance of propofol is slower in overweight/obese
animals and dogs over 8 years of age. Extra care should be taken when
administering the veterinary medicinal product to these animals; in particular, a
lower dose of propofol may be adequate for induction and maintenance in such
cases. Sighthounds have been reported to show a slower clearance of propofol
and may have a slightly longer duration of recovery from anaesthesia compared to
other breeds of dog.
Propofol does not have analgesic properties, therefore supplementary analgesic
agents should be provided in cases where procedures are anticipated to be
painful. When propofol is used concomitantly with opioids, an anticholinergic agent
(e.g. atropine) may be used in cases of bradycardia according to the benefit/risk
assessment by the responsible veterinarian. See section 3.8.
Use aseptic techniques when administering the product as it does not contain an
antimicrobial preservative.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This is a potent drug: particular care should be taken to avoid accidental self-
administration. Preferably use a guarded needle until the moment of injection.
Ampoules, particularly, should be opened with care to avoid cutting oneself.
Wash off splashes from the skin and eyes immediately.
In the case of accidental self-administration, seek medical advice immediately and
show the package leaflet or label to the physician, but DO NOT DRIVE as
sedation may occur.
Advice to doctor: Do not leave patient unattended. Maintain airways and give
symptomatic and supportive treatment.
Special precautions for the protection of the environment
Not applicable.
Propofol has been used in association with commonly used premedicants, e.g.
atropine, glycopyrrolate, α-2 agonists (medetomidine, dexmedetomidine),
acepromazine, benzodiazepines (diazepam, midazolam); inhalational agents
(halothane, isoflurane, sevoflurane, nitrous oxide, enflurane); and analgesic
agents such as pethidine and buprenorphine.
The veterinary medicinal product may be administered parallel to all intravenous
fluids via e.g. a Y-piece positioned near the injection site.
No pharmacological incompatibility has been encountered.
The emulsion should not be mixed with other therapeutic agents or infusion fluids
prior to administration.
The concurrent use of sedative or analgesic drugs is likely to reduce the dose of
propofol required to induce and maintain anaesthesia.
Concomitant use of propofol and opioids may cause significant respiratory
depression and a profound decrease in heart rate. In cats, concurrent use of
propofol and ketamine have been reported to cause apnoea more frequently than
propofol and other premedicants. To reduce the risk of apnoea, propofol should be
administered slowly over 20–60 seconds.
Co-administration of propofol and opioid (e.g. fentanyl, alfentanil) infusions for
maintenance of general anaesthesia may result in a prolonged recovery. Cardiac
arrest has been observed in dogs that received propofol followed by alfentanil.
Administration of propofol with other medicinal products that are metabolised by
cytochrome P450 (isoenzyme 2B11 in the dog) such as chloramphenicol,
ketoconazole and loperamide reduces propofol clearance and prolongs recovery
from anaesthesia.
atropine, glycopyrrolate, α-2 agonists (medetomidine, dexmedetomidine),
acepromazine, benzodiazepines (diazepam, midazolam); inhalational agents
(halothane, isoflurane, sevoflurane, nitrous oxide, enflurane); and analgesic
agents such as pethidine and buprenorphine.
The veterinary medicinal product may be administered parallel to all intravenous
fluids via e.g. a Y-piece positioned near the injection site.
No pharmacological incompatibility has been encountered.
The emulsion should not be mixed with other therapeutic agents or infusion fluids
prior to administration.
The concurrent use of sedative or analgesic drugs is likely to reduce the dose of
propofol required to induce and maintain anaesthesia.
Concomitant use of propofol and opioids may cause significant respiratory
depression and a profound decrease in heart rate. In cats, concurrent use of
propofol and ketamine have been reported to cause apnoea more frequently than
propofol and other premedicants. To reduce the risk of apnoea, propofol should be
administered slowly over 20–60 seconds.
Co-administration of propofol and opioid (e.g. fentanyl, alfentanil) infusions for
maintenance of general anaesthesia may result in a prolonged recovery. Cardiac
arrest has been observed in dogs that received propofol followed by alfentanil.
Administration of propofol with other medicinal products that are metabolised by
cytochrome P450 (isoenzyme 2B11 in the dog) such as chloramphenicol,
ketoconazole and loperamide reduces propofol clearance and prolongs recovery
from anaesthesia.
Do not store below 25 ºC. Do not freeze.
Any product remaining in the container following withdrawal of the required dose
should be discarded.
Any product remaining in the container following withdrawal of the required dose
should be discarded.
Not applicable.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Same active ingredient
Other Products Containing Propofol
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Inductofol 10 mg/ml Emulsion for Injection for Cats and Dogs
POM-VNorbrook Laboratories Limited
injection
Cats
Dogs
Norofol 10 mg/ml Emulsion for Injection for Cats and Dogs
POM-VNorbrook Laboratories Limited
injection
Cats
Dogs
Propodine 10 mg/ml Emulsion for Injection / Infusion for Dogs and Cats
POM-VDechra Regulatory BV
injection
Cats
Dogs
PropoFlo Plus, 10 mg/ml, Emulsion for Injection for Dogs and Cats
POM-VZoetis Belgium S.A.
injection
Cats
Dogs
PropoFlo Plus, 10 mg/ml, Emulsion for Injection for Dogs and Cats
POM-VZoetis UK Limited
injection
Cats
Dogs
Propomitor 10 mg/ml Emulsion for Injection/Infusion for Dogs and Cats
POM-VOrion Corporation
injection
Cats
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in anaesthetic
Related Medications
Adrenacaine Solution for Injection for Cattle
POM-VPSEpinephrine + Procaine Hydrochloride
injection
Rx
Cattle
Alfaxan Multidose 10 mg/ml Solution for Injection for Dogs, Cats and Pet Rabbits
POM-VAlfaxalone
injection
Rx
Cats
Dogs
Alfaxan Multidose 10 mg/ml Solution for Injection for Dogs, Cats and Pet Rabbits
POM-VAlfaxalone
injection
Rx
Cats
Dogs
Anaestamine 100 mg/ml Solution for Injection
POM-VKetamine
injection
Rx
Cats
Cattle
Anesketin 100 mg/ml Solution for Injection for Dogs, Cats and Horses
POM-VKetamine
injection
Rx
Cats
Dogs
Anesketin 100 mg/ml Solution for Injection for Dogs, Cats and Horses
POM-VKetamine
injection
Rx
Cats
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.